title: Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma.
abstract: The implications of aberrations in the p53 pathway for induction of apoptosis and regulation of S phase entry, and for patient survival, were investigated in 83 B-cell Non-Hodgkin's lymphomas. Eight cases had missense mutations in exons 5, 7, 8 and 9 as revealed by constant denaturant gel electrophoresis and sequencing. Fifteen cases had lost 1 TP53 allele as revealed by fluorescent in situ hybridization and comparative genomic hybridization. Ten cases expressed high levels of p53 as assessed by immunoblotting and immunohistochemistry. S phase fractions were higher, apoptotic fractions were the same and survival times were shorter in all aberration groups compared with the cases with no TP53/p53 aberrations. Since many tumors had more than one TP53/p53 aberration, the tumors were divided into groups with the following characteristics: no TP53/p53 aberrations; loss of one TP53 allele only (9 cases), TP53 point mutation (8 cases), high-level p53 expression and no TP53 mutation (3 cases). Tumors from the 3 latter groups had higher median S phase fractions (5%, 7.6%, and 5%, respectively, p<0.02) than the cases without any aberrations (1.1%), and survival time for these patients was much shorter (relative risks of 5.9, 8.9, and 6.6, respectively, p<0.003). Apoptotic fractions were similar in all these groups (p=0.09). Multivariate analysis showed that the presence of TP53/p53 aberrations is a strong and independent prognostic parameter in B-cell Non-Hodgkin's lymphoma.
authors.affiliation: Department of Biophysics, The Norwegian Radium Hospital, Montebello, Oslo, Norway. tstokke@radium.uio.no
authors.forename: T
authors.initials: T
authors.lastname: Stokke
authors.forename: E
authors.initials: E
authors.lastname: Galteland
authors.forename: H
authors.initials: H
authors.lastname: Holte
authors.forename: L
authors.initials: L
authors.lastname: Smedshammer
authors.forename: Z
authors.initials: Z
authors.lastname: Suo
authors.forename: E B
authors.initials: EB
authors.lastname: Smeland
authors.forename: A L
authors.initials: AL
authors.lastname: Børresen-Dale
authors.forename: P
authors.initials: P
authors.lastname: DeAngelis
authors.forename: H B
authors.initials: HB
authors.lastname: Steen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000235:genetics; D005091:Exons; D005260:Female; D017353:Gene Deletion; D015870:Gene Expression; D016158:Genes, p53 / Q000235:genetics*; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D010641:Phenotype; D017354:Point Mutation; D011379:Prognosis; D012189:Retrospective Studies; D016196:S Phase / Q000235:genetics*; D016019:Survival Analysis; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology
chemical_list: D016159:Tumor Suppressor Protein p53